{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:36Z","timestamp":1740148236457,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk of bleeding while anticoagulated. In addition, cancer therapies have been associated to increased VTE risk. Guidelines for VTE treatment in cancer patients recommend low molecular weight heparins (LMWH) or direct oral anticoagulants (DOAC) for the initial treatment, DOAC for VTE short-term treatment, and LMWH or DOAC for VTE long-term treatment. This consensus article arises from a collaboration between different Spanish experts on cancer-associated thrombosis. It aims to reach an agreement on a practical document of recommendations for action allowing the healthcare homogenization of cancer-associated thrombosis (CAT) patients in Spain considering not only what is known about VTE management in cancer patients but also what is done in Spanish hospitals in the clinical practice. The text summarizes the current knowledge and available evidence on the subject in Spain and provides a series of practical recommendations for CAT management and treatment algorithms to help clinicians to manage CAT over time.<\/jats:p>","DOI":"10.1007\/s12094-023-03379-z","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T15:02:26Z","timestamp":1707836546000},"page":"1319-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients\u2019 healthcare in Spain"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-8249","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Mu\u00f1oz Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Javier","family":"Trujillo-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-2916","authenticated-orcid":false,"given":"Edelmira","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Jara-Palomares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Mac\u00edas Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-3488","authenticated-orcid":false,"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1226-2353","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"L\u00f3pez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Brozos-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Robles-Marinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Ru\u00edz-Artacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"3379_CR1","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.3892\/etm.2019.8019","volume":"18","author":"RA Iorga","year":"2019","unstructured":"Iorga RA, Bratu OG, Marcu RD, Constantin T, Mischianu DLD, Socea B, et al. Venous thromboembolism in cancer patients: Still looking for answers. Exp Ther Med. 2019;18:5026\u201332. https:\/\/doi.org\/10.3892\/etm.2019.8019.","journal-title":"Exp Ther Med"},{"key":"3379_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1358863X18755928","volume":"23","author":"NS Evans","year":"2018","unstructured":"Evans NS, Ratchford EV. Superficial vein thrombosis. Vasc Med. 2018;23:187\u20139. https:\/\/doi.org\/10.1177\/1358863X18755928.","journal-title":"Vasc Med"},{"key":"3379_CR3","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1002\/onco.13584","volume":"26","author":"C O\u2019Connell","year":"2021","unstructured":"O\u2019Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist. 2021;26:e8\u201316. https:\/\/doi.org\/10.1002\/onco.13584.","journal-title":"Oncologist"},{"key":"3379_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11239-019-02032-3","volume":"50","author":"JD Guo","year":"2020","unstructured":"Guo JD, Hlavacek P, Poretta T, Wygant G, Lane D, Gorritz M, et al. Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States. J Thromb Thrombolysis. 2020;50:386\u201394. https:\/\/doi.org\/10.1007\/s11239-019-02032-3.","journal-title":"J Thromb Thrombolysis"},{"key":"3379_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/rth2.12215","volume":"3","author":"GA Soff","year":"2019","unstructured":"Soff GA, Mones J, Wilkins C, Devlin S, Haegler-Laube E, Wills J, et al. Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost. 2019;3:349\u201356. https:\/\/doi.org\/10.1002\/rth2.12215.","journal-title":"Res Pract Thromb Haemost"},{"key":"3379_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:1181\u2013201. https:\/\/doi.org\/10.6004\/jnccn.2021.0047.","journal-title":"J Natl Compr Canc Netw"},{"key":"3379_CR7","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23:e334\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00160-7.","journal-title":"Lancet Oncol"},{"key":"3379_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442.","journal-title":"Blood Adv"},{"key":"3379_CR9","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41:3063\u201371. https:\/\/doi.org\/10.1200\/JCO.23.00294.","journal-title":"J Clin Oncol"},{"key":"3379_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","volume":"22","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Gallardo D\u00edaz E, Garc\u00eda Escobar I, Mac\u00edas Montero R, Mart\u00ednez-Mar\u00edn V, Pach\u00f3n Olmos V, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020;22:171\u201386. https:\/\/doi.org\/10.1007\/s12094-019-02263-z.","journal-title":"Clin Transl Oncol"},{"key":"3379_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507.","journal-title":"N Engl J Med"},{"key":"3379_CR12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"Hokusai-VTE Investigators, B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp SP, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1306638.","journal-title":"N Engl J Med"},{"key":"3379_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14740338.2019.1601699","volume":"18","author":"M Kimpton","year":"2019","unstructured":"Kimpton M, Carrier M. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Expert Opin Drug Saf. 2019;18:313\u201320. https:\/\/doi.org\/10.1080\/14740338.2019.1601699.","journal-title":"Expert Opin Drug Saf"},{"key":"3379_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1711948.","journal-title":"N Engl J Med"},{"key":"3379_CR15","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017\u201323. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034.","journal-title":"J Clin Oncol"},{"key":"3379_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1915103.","journal-title":"N Engl J Med"},{"key":"3379_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","volume":"21","author":"AJ Lloyd","year":"2018","unstructured":"Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AYY. What impact does venous thromboembolism and bleeding have on cancer patients\u2019 quality of life? Value Health. 2018;21:449\u201355. https:\/\/doi.org\/10.1016\/j.jval.2017.09.015.","journal-title":"Value Health"},{"key":"3379_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/cncr.32724","volume":"126","author":"A Li","year":"2020","unstructured":"Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, Garcia DA, et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020;126:1736\u201348. https:\/\/doi.org\/10.1002\/cncr.32724.","journal-title":"Cancer"},{"key":"3379_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/13696998.2022.2087998","volume":"25","author":"A Mu\u00f1oz","year":"2022","unstructured":"Mu\u00f1oz A, Gallardo E, Agnelli G, Crespo C, Forghani M, Arumi D, et al. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. J Med Econ. 2022;25:840\u20137. https:\/\/doi.org\/10.1080\/13696998.2022.2087998.","journal-title":"J Med Econ"},{"key":"3379_CR20","unstructured":"SEC-PRIMARIA. Proyecto integrador de Cardiolog\u00eda y Atenci\u00f3n Primaria - Sociedad Espa\u00f1ola de Cardiolog\u00eda https:\/\/secardiologia.es\/publicaciones\/catalogo\/libros\/13643-sec-primaria-proyecto-integrador-de-cardiologia-y-atencion-primaria.Accessed 30 Nov 2022"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03379-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T09:24:30Z","timestamp":1716283470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03379-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03379-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AJMM: Consultant or Advisory role of Pfizer-BMS, Sanofi, Celgene, Leo Pharma, Incyte, Astra-Zeneca, MSD, Lilly, Servier, Bayer, Roche, GSK; Research funding from Celgene, Sanofi, Leo Pharma, Rovi; Speakers\u2019 bureau for Rovi, Bayer, Menarini, Stada, Daichii Sankyo; Patents, Royalties, Other Intellectual Property: Risk assessment model of venous thromboembolism in cancer patients. EM: personal fees from Daiichi-Sankyo, Bristol-Myers, Bayer, Pfizer, Boehringher Ingelheim, LeoPharma and Rovi outside the submitted work. LJP: personal fees from Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Rovi, Pfizer, Bristol-Myers Squibb, MSD and Leo Pharma. EG: Consultant or Advisory Role for Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, EUSA Pharma, BMS, MSD, AstraZeneca, Merck, Rovi, Daiichi Sankyo, Techdow, Lilly, Advanced Accelerator Applications. Speaking: Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Eisai, Boehringer Ingelheim, Merck, EUSA Pharma, Lilly, Advanced Accelerator Applications. Grant support: Astellas, Janssen, Sanofi, Bayer, Ipsen, Ferrer, Pfizer, Roche, GSK, BMS. Travel\/acommodation expenses: Astellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pierre Fabre, Pfizer, Eisai, AstraZeneca. VRM: advisor or consultant for Pfizer, Bayer; speaker for Pfizer, Bayer, Daiichi Sankyo, Rovi, GSK, Bristol-Myers Squibb. PRA: advisor or consultant for Leo Pharma, Pfizer and Viatris; speaker or member of a speakers\u2019 bureau for Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, ROVI and Viatris; grants for clinical research from ROVI. The other authors did not report any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an article about the management of patients in hospitals from experts' opinion. No research involving human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"No informed consent need.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}